• Wed news: Medicare $2 generics. Biogen’s high-dose Spinraza. Roche breast cancer trial. Lilly’s unique AI deal. Sage Alzheimer’s fail. See more on our front page

Activist Investor 1.0b stake today









Why Pfizer Will Find It Hard to Appease Its Activist Investor
The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.
Source: WSJ
 




Why Pfizer Will Find It Hard to Appease Its Activist Investor
The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.
Source: WSJ
All true, plus the rich payout that the moron AB will get.
That said, I’m pulling for Starboard. We are mired in the this mess created by AB and we must have some catalyst to break out.
 




Similar threads

Replies
7
Views
1K
Pfizer
anonymous